Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

(2010) R E Coleman et al.   BRITISH JOURNAL OF CANCER

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

(2010) Mohamed S. Zaghloul et al.   International Journal of Clinical Oncology

Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?

(2010) Michael Gnant   JOURNAL OF CLINICAL ONCOLOGY

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

(2010) E Terpos et al.   LEUKEMIA

The Molecular Basis of Bisphosphonate Activity: A Preclinical Perspective

(2010) Jonathan Green et al.   SEMINARS IN ONCOLOGY

Potential Anticancer Properties of Bisphosphonates

(2010) Helen L. Neville-Webbe et al.   SEMINARS IN ONCOLOGY

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro

(2009) Johanna Räikkönen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells

(2009) Tilman D. Rachner et al.   CANCER LETTERS

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer

(2009) Vera Hirsh   Clinical Lung Cancer

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis

(2009) Kostantinos Zarogoulidis et al.   INTERNATIONAL JOURNAL OF CANCER

Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo

(2009) Anke J Roelofs et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

(2009) David P Dearnaley et al.   LANCET ONCOLOGY

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer

(2009) Kishan J. Pandya et al.   LUNG CANCER

Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis

(2009) Manav Korpal et al.   NATURE MEDICINE

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting

(2009) Mateya Trinkaus et al.   SUPPORTIVE CARE IN CANCER

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells

(2008) Fraser P. Coxon et al.   BONE

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients

(2008) Daniele Santini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis

(2008) Peyman Hadji   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Anti-Angiogenic Property of Zoledronic Acid by Inhibition of Endothelial Progenitor Cell Differentiation

(2008) Jun Yamada et al.   JOURNAL OF SURGICAL RESEARCH

Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

(2008) Vera Hirsh et al.   Journal of Thoracic Oncology

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells and unwitting host to molecular parasites

(2008) Y Shiozawa et al.   LEUKEMIA

New research findings on zoledronic acid: Survival, pain, and anti-tumour effects

(2007) Fred Saad   CANCER TREATMENT REVIEWS